Post by Unlearn.AI

Our team presented at the 5th ALS Drug Development Summit in Boston last week, sharing new data on the use of #digitaltwins as synthetic control arms in ALS #clinicaltrials. The poster examined how AI-generated, patient-level digital twins can serve as external comparators in non-randomized #ALS studies — addressing one of the central challenges in early-phase development: generating interpretable efficacy signals without a concurrent control group. Thank you to everyone who connected with us! We look forward to continuing the conversation! 🚀 ——— Hanson Wade, Luis Olmos, PhD, MBA, Anurag Kulkarni, Tricia Sorrentino